COVID-19 Associated Coagulopathy in Egypt

Assessment of COVID-19 Associated Coagulopathy and Hypercoagulable State in Upper Egypt

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04507230

Enrollment

106

Registered

2020-08-11

Start date

2020-08-07

Completion date

2020-10-31

Last updated

2021-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coagulopathy

Keywords

hypercoagulable, COVID-19

Brief summary

Coagulopathy is one of the most significant prognostic factors in patients with COVID-19 and is associated with increased mortality and admission to critical care. Most commonly observed coagulopathy in patients hospitalized with COVID-19 (COVID-19-associated coagulopathy) is characterized by increased D-dimer and fibrinogen levels. 71% of patients who did not survive hospitalization reported to have developed disseminated intravascular coagulation (DIC) compared to 0.6% of survivors.

Detailed description

studying the detailed coagulation screen and second line coagulation parameters including both thrombophilia screen and other acute phase coagulation factors.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients with COVID 19 positive by RT- PCR

Exclusion criteria

* no exclusions

Design outcomes

Primary

Measure	Time frame	Description
Coagulation screen	1 month	Full coagulation screen
Thrombophilia screen	1 month	Full thrombophilia screen
VWF, FVIII	1 month	VWFAg, FVIII

Countries

Egypt

Outcome results